Market Research Store

PharmaPoint: Alzheimers
Disease Market
Size, Share, Global Trends,
Analysis, Research Report
and Forecast,
2015-2023

www.marketresearchstore.com

sales@marketresearchstore.com

Market PharmaPoint: Alzheimers Disease Market ,

Global Drug Forecast and Market Analysis 2023
Alzheimers Disease (AD) is a progressive neurodegenerative disease that
is characterized by memory loss, cognitive impairment, and functional
decline. During the early stages of disease, sleep disturbances and
forgetfulness are generally the first presenting symptoms. In the severe
stages, patients with AD require permanent observation either by a home
care professional or family member. The rapidly declining status of
patients with AD results in a drastic reduction in quality of life (QOL),
both for the patients and their caretakers. With rapidly accelerating
worldwide prevalence, AD has been identified as a major global health

threat by the international medical community. Significant efforts have

been made to develop a new treatment for AD, as current pharmacologic
management is known to only provide temporary improvement of
symptoms. Without therapies that effectively stop or reverse the course
of the disease, a large area opportunity exists for the development of an
effective pharmacologic approach.

Read Complete Report with TOC:

http://www.marketresearchstore.com/report/pharmapoint-alzheimersdisease-global-drug-forecast-and-13807

Highlights
Key Questions Answered

What are the preferred therapies for each country?

The developmental pipeline consists of disease-modifying therapies
(DMTs) that aim to prevent the disease in early- and
presymptomatic patients. Which of these DMTs will attain high sales
revenues during 2013-2023, and in which markets?
Will amyloid-based therapies face adoption challenges in the
market? What is the projected uptake of new passive
immunotherapies and BACE inhibitors over the forecast period?
How large an impact will Lundbecks LuAE-58054 and

Forum/Mitsubishi Tanabes EVP-6124 have on the schizophrenia

market? What do key opinion leaders think of these treatment
approaches?
What are the unique challenges in AD, and how will they affect the
growth of the market globally?

Key Findings

o Guidelines are not closely followed due to the heterogeneity of

symptoms.
o There is a widespread reluctance to seek treatment in the
absence of curative therapies.

o Diagnosis in early stages of the disease remains a challenge

and will affect the growth of the market over the 2013-2023
forecast period.
o Poor consensus over clinical trial endpoints required for
approval.
o Symptoms related to AD require better treatment options.
o Amyloid beta is the focus of the late-stage pipeline.
o Disease-modifying therapies such as passive immunotherapies
and BACE inhibitors will revitalize the AD market.

Scope

Overview of AD and mild cognitive impairment (MCI), including

etiology, general symptoms, country-specific
compliance/caregiving data and epidemiology.
Annualized AD market revenue, annual cost of treatment and
usage patterns from 2013 and forecast for ten years to 2023.
Key topics covered include strategic competitor assessment,
unmet needs, clinical trial mapping and implications for the AD
market.
Pipeline analysis: comprehensive data split across AD disease
severities for disease-modifying and symptomatic therapies

with novel mechanisms of action in AD, including Lillys

solanezumab, Roches gantenerumab and crenezumab (Phase
II). Merck & Co.s M-8931, and Lilly/AstraZenecas AZD-3293.
Analysis of the current and future market competition in the
global AD drug market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.

Reasons to buy

Develop and design your in-licensing and out-licensing

strategies through a review of pipeline products and

technologies, and by identifying the companies with the most

competitive pipelines.
Develop business strategies by understanding the trends
shaping and driving the AD market.
Drive revenues by understanding the key trends, innovative
products and technologies, market segments, and companies
likely to impact the global AD market in the future.
Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the
performance of various competitors.
Identify emerging players with potentially strong product
portfolios and create effective counter-strategies to gain a

competitive advantage.
Track drug sales in the global AD market from 2013-2023.
Organize your sales and marketing efforts by identifying the
market categories and segments that present maximum
opportunities for consolidations, investments and strategic
partnerships.

Get Sample Copy of Report:

http://www.marketresearchstore.com/report/pharmapoint-alzheimersdisease-global-drug-forecast-and-13807#requestSample

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 27
3.1.2 Pathophysiology 29

3.2 Disease Staging Systems 38

3.3 Symptoms 41
3.4 Prognosis 43
3.5 Quality of Life 43
4 Epidemiology 45
4.1 Disease Background 45
4.2 Risk Factors and Comorbidities 46
4.2.1 A family history of Alzheimers increases the risk of developing the
disease by 7.5 times 47

Read More: http://www.marketresearchstore.com/report/pharmapointalzheimers-disease-global-drug-forecast-and-13807

About Us
Market Research Store is a single destination for all the industry,
company and country reports. We feature large repository of latest
industry reports, leading and niche company profiles, and market
statistics released by reputed private publishers and public
organizations.

Contact Us
TELEPHONE: +1-386-310-3803 Us:Stay

With
E-MAIL:
sales@marketresearchstore.com

Suite #8138, 3422 SW

15 Street,
Deerfield Beach, Florida
33442
United States